Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 150 participants.

Also called NCT07102511

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07102511
  • EU CT 2025-524214-28-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Israel, New Zealand, Norway, South Africa, Türkiye (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT07102511. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-20 (actual); primary completion 2028-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH
Acronym
LIBerateKids
Condition
Familial Hypercholesterolemia - Heterozygous
Intervention (Biological)
lerodalcibep 300 mg Monthly SC
Lead sponsor
LIB Therapeutics LLC (class: industry)
Collaborator
Medpace, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07102511
Content hash
f9a060fe26ed44b7aaa1b36084481fd6802f2b9f13ce2329a5f0c061896389f6